INVESTIGATION OF CROSS IMMUNITY FOLLOWING VACCINATION WITH ALLOGENIC CANCER CELL

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We are currently conducting a lung cancer clinical vaccine trial which is using gene modified cancer cells. The design of this ongoing vaccine study is geared to investigate whether immunity specifically directed against the allogenic cell lines used as the actual vaccine will develop. Appropriate assays will be performed which includes cytotoxic T-lymphocyte assays, as well as cytokine assays and clinical evaluation for tumor responses. Participating subjects already have provided appropriate consents. In order to perform additional important immunological assays from archived blood, we propose and investigator initiated component. We propose to examine whether a response against other lung cell lines has developed. This response would be specifically against cell lines the subjects had not been vaccinated during the vaccination process. These studies will be performed on lymphocytes and serum obtained from naive subjects (prior to vaccination) and subjects following each of the four vaccinations. These tissues and serum are archived and cryopreserved and propsed studies will be conducted in vitro.